Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Verity Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activ...
Product Name : Natesto
Product Type : Hormone
Upfront Cash : Undisclosed
October 01, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Verity Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.
Product Name : Noctiva
Product Type : Hormone
Upfront Cash : Undisclosed
September 03, 2022
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Testosterone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Recipient : University of Utah
Deal Size : Inapplicable
Deal Type : Inapplicable
Natesto Testosterone Nasal Gel for Hypogonadal Men
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Recipient : University of Utah
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Study Phase : Approved FDF
Recipient : Serenity LLC
Deal Size : $16.0 million
Deal Type : Agreement
Acerus Announces Definitive Agreement to Acquire Serenity LLC and The Global Rights To NOCTIVA™
Details : Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.
Product Name : Noctiva
Product Type : Hormone
Upfront Cash : $6.0 million
February 28, 2022
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Recipient : Serenity LLC
Deal Size : $16.0 million
Deal Type : Agreement
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®
Details : Under the terms of the agreement, Amneal will sell NATESTO, Testosterone Nasal gel to the company’s existing Endocrinology targets through June 30, 2024.
Product Name : Natesto
Product Type : Hormone
Upfront Cash : Undisclosed
October 05, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Aytu BioPharma
Deal Size : $7.5 million
Deal Type : Divestment
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
Details : Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.
Product Name : Natesto
Product Type : Hormone
Upfront Cash : $7.5 million
January 04, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Aytu BioPharma
Deal Size : $7.5 million
Deal Type : Divestment
Lead Product(s) : Testosterone Cypionate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Recipient : University of Miami
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2020
Lead Product(s) : Testosterone Cypionate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Recipient : University of Miami
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Testosterone Nasal Gel in Hypogonadal Boys
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 17, 2017
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Recipient : University of Miami
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 29, 2017
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Recipient : University of Miami
Deal Size : Inapplicable
Deal Type : Inapplicable